Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030- Product Image

Sale

Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030

Report
181 Pages
October 2024
Region: Global
360iResearch™
ID: 5896370

UP TO €681EUR$697USD£569GBP OFF until Dec 31^st 2024

The Antibody Drug Conjugate Market grew from USD 5.60 billion in 2023 to USD 6.48 billion in 2024. It is expected to continue growing at a CAGR of 16.12%, reaching USD 15.96 billion by 2030.

Antibody Drug Conjugates (ADCs) represent a burgeoning sector within the biopharmaceutical market, designed to deliver cytotoxic drugs directly to cancer cells with high specificity, thus sparing healthy cells and potentially reducing systemic toxicity. The necessity for ADCs arises from the need for more targeted cancer therapies, addressing the limitations of conventional chemotherapy by combining the specificity of monoclonal antibodies with the potency of high-grade chemotherapy drugs. Their application is predominantly focused on oncology, but research into other therapeutic areas, such as autoimmune diseases and infectious diseases, is underway. The end-use scope predominantly includes hospitals, specialty cancer research centers, and biotechnology companies.

Market growth for ADCs is influenced by key factors like technological advancements in antibody engineering, ongoing research, and increasing incidences of cancer worldwide. Recent potential opportunities lie in the identification and validation of novel biomarkers and targets, and the development of next-generation ADCs with enhanced therapeutic indices. Companies are encouraged to invest in research collaborations and partnerships to drive innovation and access emerging markets. Nonetheless, market growth faces significant limitations such as high development costs, complex manufacturing processes, and regulatory challenges, which can hinder timely product launches. Moreover, the market is challenged by the economic burden of ADC therapies, affecting their adoption and accessibility globally.

Forward-looking areas for innovation include engineering more stable linkers to improve drug delivery and developing new payload classes to expand the types of treatable cancers. Businesses should also explore novel conjugation methods that offer increased precision and better pharmacokinetic profiles. From a market nature perspective, the ADC market is highly competitive and dynamic, driven by rapid research advancements and frequent strategic alliances and acquisitions. Companies able to capitalize on these elements, while navigating current constraints, stand poised to capture significant growth potential in the upcoming years.

Understanding Market Dynamics in the Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of cancer worldwide
- Growth in clinical trial activities and robust product pipeline
- Government support and initiatives encouraging research on cancer
Market Restraints
- High manufacturing cost of ADC and incidences of product recalls
Market Opportunities
- Increasing investment in biopharma R&D and introduction of novel ADCs
- Adoption of advanced technologies for developing ADC
Market Challenges
- Complexity in manufacturing of ADCs

Exploring Porter’s Five Forces for the Antibody Drug Conjugate Market

Porter’s Five Forces framework further strengthens the insights of the Antibody Drug Conjugate Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antibody Drug Conjugate Market

External macro-environmental factors deeply influence the performance of the Antibody Drug Conjugate Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism of Action
- CD30 Antibodies
- ErbB2 Antibodies
Drugs
- Adcetris
- Blenrep
- Enhertu
- Kadcyla
- Padcev
- Trodelvy
Technology
- Cleavable Linker
- Linkerless
- Non-Cleavable Linker
Indication
- Blood Cancer
- Breast Cancer
- Lymphoma
- Multiple Myeloma
- Urothelial Cancer & Bladder Cancer
End User
- Academic Research Institutes
- Biopharmaceutical & Biotechnology Companies
- Hospitals
- Specialized Cancer Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - Alaska
    - California
    - Florida
    - Illinois
    - Massachusetts
    - Michigan
    - Montana
    - Nevada
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in clinical trial activities and robust product pipeline
5.1.1.3. Government support and initiatives encouraging research on cancer
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
5.1.3.2. Adoption of advanced technologies for developing ADC
5.1.4. Challenges
5.1.4.1. Complexity in manufacturing of ADCs
5.2. Market Segmentation Analysis
5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Antibody Drug Conjugate Market, by Mechanism of Action

6.1. Introduction
6.2. CD30 Antibodies
6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

7.1. Introduction
7.2. Adcetris
7.3. Blenrep
7.4. Enhertu
7.5. Kadcyla
7.6. Padcev
7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Lymphoma
9.5. Multiple Myeloma
9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical & Biotechnology Companies
10.4. Hospitals
10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

List of Figures

FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 77. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 82. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 92. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 122. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 138. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 143. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 148. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 184. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 187. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 188. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 193. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 242. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antibody Drug Conjugate market, which are profiled in this report, include:

Abbott Laboratories
AbbVie Inc.
ADC Therapeutics SA
Ambrx Biopharma Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
BioNTech SE
Bristol-Myers Squibb Company
Byondis B.V.
Celldex Therapeutics Inc.
Creative Biolabs, Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Heidelberg Pharma AG
ImmunoGen, Inc.
Innate Pharma SA
Innovent Biologics, Inc.
Lonza Group Ltd.
MacroGenics, Inc.
MediLink Therapeutics
Merck KGaA
Mersana Therapeutics, Inc.
Novartis AG
Oxford Biotherapeutics Limited
Pfizer, Inc.
Pheon Therapeutics Ltd.
Piramal Pharma Limited
Recipharm AB
Sanofi S.A.
Sorrento Therapeutics, Inc.
Tagworks Pharmaceuticals BV
Takeda Pharmaceutical Company Limited
Tubulis GmbH
Zymeworks Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 6.48 Billion
Forecasted Market Value ( USD ) by 2030	$ 15.96 Billion
Compound Annual Growth Rate	16.1%
Regions Covered	Global
No. of Companies Mentioned	39

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3466EUR$3,545USD£2,895GBP €3851EUR$3,939USD£3,217GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6132EUR$6,272USD£5,122GBP €6813EUR$6,969USD£5,691GBP

Understanding Market Dynamics in the Antibody Drug Conjugate Market

Exploring Porter’s Five Forces for the Antibody Drug Conjugate Market

Applying PESTLE Analysis to the Antibody Drug Conjugate Market

Analyzing Market Share in the Antibody Drug Conjugate Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antibody Drug Conjugate Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

Antibody Drug Conjugate - Market Insights, Competitive Landscape, and Market Forecast - 2030

Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030

Antibody Drug Conjugates (ADC) - Global Strategic Business Report